On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Cybin Corp. at Forefront of Change in Psilocybin-Based Treatments

  • Company focused on furthering R&D of psilocybin-based medications
  • Cybin believes psychedelic substances derived from mushrooms can work as boosters for brain
  • Psilocybin shows promise for an array of mental health issues

Cybin Corp. is a leading life-science company focused on psychedelic and nutraceutical products to support various psychiatric and neurological conditions. The company is engaged in clinical trials, through a partnership with the Toronto Centre for Psychedelic Science (“TCPS”) to gain regulatory approval for psilocybin and other psychedelic products (http://nnw.fm/HKsW4).

In the 1940s, the study of psychedelic drugs for the treatment of mental health conditions began with the discovery of LSD. However, President Richard Nixon put a stop to this research in the 1960s with his war on drugs. Only recently have researchers began to explore psychedelics once again. This research is showing positive results in the treatment of depression, anxiety, PTSD, addictions, eating disorders, ADHD and more.

This evolution couldn’t be more timely. In the midst of a worldwide pandemic, the need for anxiety-reducing therapies has grown substantially, and psychedelics may have the potential to make a profound impact. Clinical studies for PTSD and psilocybin therapy for treatment-resistant depression has won the acknowledgment of the FDA (http://nnw.fm/jzG2r). The combined cooperation of the FDA and investors is breaking down previous barriers. Psychedelic treatment may soon become mainstream.

Cybin believes that psychedelic substances derived from mushrooms can work as boosters for the brain, potentially rebuilding pathways and breaking negative patterns. Today more than 700 million people around the world struggle with mental illness, addiction or eating disorders — all areas where the benefits of psychedelic substances is being studied. What’s more, even though over 40 million Americans are taking psychiatric drugs, Big Pharma has not produced any new drug innovations in the last ten years (http://nnw.fm/RT9bI).

The world is changing quickly, and people are looking for new and improved options for managing their health. Right now, only 10% of fungi species are taxonomically classified, leaving an enormous potential for future medical research. Cybin is at the forefront of that research, paving the way for new advances and leveraging its expertise in the world of medicinal mushrooms.

Cybin operates in the functional-mushroom market with a goal to develop fungi-derived medicinal products to treat mental illness and other health conditions. The business model of this early-stage, life-sciences company includes two wholly owned core subsidiaries: Serenity Life Sciences, focusing on advancing research and development of psilocybin-based pharmaceutical products, and Natures Journey Inc., developing medicinal nonpsychedelic nutraceutical products.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.networknewswire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 212.418.1217